A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid Malignancies
NCT02966171
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
14
Enrollment
INDUSTRY
Sponsor class
Stopped
The study was terminated on 23AUG2018 for safety reasons.
Conditions
Solid Tumor
Interventions
DRUG:
HMPL-453
Sponsor
Hutchison Medipharma Limited